Post Marketing Surveillance Study of the Labeled Use of Remicade (Infliximab) in Patients With Chronic Inflammatory Diseases

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infliximab (Primary)
Indications Ankylosing spondylitis; Crohn's disease; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
Focus Adverse reactions
Acronyms REMission
Sponsors Merck & Co; Merck Sharp & Dohme Corp.; Schering-Plough

Most Recent Events

11 Sep 2012 Drug company changed from Schering Plough to Merck & Co as reported by ClinicalTrials.gov.
17 Oct 2011 Actual patient no is 3000 as reported by ClinicalTrials.gov.
13 Oct 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight